Novartis (NVS) Q2 2026 Earnings: Core EPS Beats Estimates on +3% Sales Growth
Key Takeaways
- Novartis reported Q2 2026 net sales of $14.4 billion, up 3% year-over-year in USD terms.
- Core earnings per share came in at $2.41, slightly below the prior year but ahead of analyst consensus estimates around $2.16–$2.17.
- Reported net income declined to $3.3 billion from $4.0 billion a year earlier due to one-time factors.
- Core operating income remained essentially flat year-over-year at $5.9 billion.
- Free cash flow totaled $5.6 billion, down from $6.3 billion in the prior-year quarter.
- Shares reacted positively in after-hours trading following the better-than-expected core results.
Why These Results Matter for Investors
Novartis, a leading global pharmaceutical company, delivers quarterly results that provide investors with critical updates on its innovative medicines portfolio, including key growth drivers in oncology, cardiology, and neuroscience. The Q2 2026 report arrives amid steady demand for its flagship products and ongoing pipeline advancements. Earnings season for healthcare firms like Novartis often influences broader sector sentiment, as results can signal trends in drug pricing, regulatory approvals, and competitive dynamics. Strong or weak performance here can affect investor confidence in the company’s ability to sustain long-term growth in a high-stakes industry.
Q2 2026 Financial Results Breakdown
Novartis announced its Q2 2026 financial results on July 21, 2026. Net sales reached $14.408 billion, representing a 3% increase from $14.054 billion in Q2 2025 (1% growth in constant currencies). Core operating income held steady at $5.94 billion. Core net income was $4.578 billion, and core earnings per share (EPS) came in at $2.41, essentially flat year-over-year on a constant-currency basis. Reported net income fell 19% to $3.257 billion, with reported EPS at $1.71, reflecting the impact of certain non-core items. The company’s core EPS exceeded consensus analyst estimates of approximately $2.16–$2.17. Revenue also topped expectations near $14.12 billion. Operating income and free cash flow showed modest declines compared with the prior year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Following the July 21 release, Novartis shares rose in after-hours trading as investors focused on the earnings beat and resilient core performance. The positive reaction reflected relief that core metrics met or exceeded expectations despite a reported net income decline driven by non-recurring items. Broader market sentiment toward the healthcare sector remained constructive, with analysts highlighting the company’s ability to maintain core profitability amid evolving industry conditions.
Forward Outlook and Key Factors to Monitor
Investors will next focus on Novartis’ full-year guidance and any updates provided during the earnings call. Key areas to watch include the performance of leading products in oncology and other therapeutic areas, as well as progress on the company’s research and development pipeline.
Cost management, currency fluctuations, and potential regulatory or competitive developments in key markets could influence results in coming quarters. Margin trends and free cash flow generation will also remain important indicators of operational efficiency.
Upcoming catalysts such as new product launches, clinical trial readouts, or strategic partnerships may shape the outlook. Broader industry dynamics, including healthcare policy changes and pricing pressures, warrant continued attention as the company navigates the second half of the year. From what I see, monitoring these elements closely will be important for understanding the sustainability of the core performance.
My Experience with Tickeron’s AI Tools
In my own research process, I often turn to Tickeron’s AI Screener for deeper market scans. This AI-powered stock and ETF discovery tool helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
NVS in upward trend: price rose above 50-day moving average on July 21, 2026
NVS moved above its 50-day moving average on July 21, 2026 date and that indicates a change from a downward trend to an upward trend. In of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where NVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in of 340 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 312 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVS as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVS turned negative on August 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NVS broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.969) is normal, around the industry mean (19.737). P/E Ratio (23.009) is within average values for comparable stocks, (31.297). Projected Growth (PEG Ratio) (3.477) is also within normal values, averaging (11.505). Dividend Yield (0.031) settles around the average of (0.030) among similar stocks. P/S Ratio (5.179) is also within normal values, averaging (4.098).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement